1. Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase.
- Author
-
Perusini, Maria Agustina, Andrews, Claire, Atenafu, Eshetu G., Gupta, Vikas, Maze, Dawn, Schuh, Andre C., Yee, Karen WL., Bankar, Aniket, Davidson, Marta B., Richard-Carpentier, Guillaume, Chan, Steven M., Sibai, Jad, Schimmer, Aaron D., Minden, Mark D., and Sibai, Hassan
- Subjects
- *
LYMPHOBLASTIC leukemia , *OLDER patients , *ACUTE leukemia , *OVERALL survival , *FEBRILE neutropenia - Abstract
This retrospective report presents the outcomes and adverse events (AEs) observed in 73 patients aged 60 years or older diagnosed with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (Ph-negative ALL) treated with a pediatric-inspired protocol incorporating either Pegylated (PEG-ASP) or Native Asparaginase (EC-ASP). Notably, 61% of patients experienced AEs of Grade III-IV severity. The most prevalent AEs included thrombosis (35.6%), febrile neutropenia (38.4%), and transaminitis (34.2%). AEs did not translate into significant differences concerning overall survival, leukemia-free survival, or early mortality. Furthermore, we observed a reduction in early mortality rates (11% vs. 20%) and an increase in median overall survival (54 vs. 48 months) compared to our previous data. These findings suggest that the utilization of a pediatric-inspired chemotherapy protocol, with ASP, is an effective and well-tolerated therapeutic option for older patients with Ph-negative ALL. However, it emphasizes the importance of diligent monitoring and close follow-up throughout treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF